Kimberly Massey
Family · Ashburn, GANPI 1598197725
Payments from drug & device makers
Across 278 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$853
- GSK$475
- Corcept Therapeutics$423
- Lilly USA, LLC$417
- AbbVie$293
- AstraZeneca$289
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,085100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $853 |
| GSK | 24 | $475 |
| Corcept Therapeutics | 15 | $423 |
| Lilly USA, LLC | 28 | $417 |
| AbbVie | 19 | $293 |
| AstraZeneca | 18 | $289 |
| Bayer | 12 | $288 |
| Kowa Pharmaceuticals America, Inc. | 19 | $282 |
| Dexcom, Inc. | 9 | $202 |
| Amgen | 12 | $188 |
| Ironwood Pharmaceuticals, Inc | 12 | $183 |
| Boehringer Ingelheim | 11 | $180 |
| Paratek Pharmaceuticals, Inc. | 9 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $148 |
| Novartis | 7 | $142 |
| Sanofi-aventis U.S. LLC | 5 | $99 |
| Pfizer | 6 | $97 |
| Merck | 5 | $84 |
| Abbott | 1 | $76 |
| Medicure Pharma Inc. | 1 | $65 |
| Eisai Inc. | 1 | $29 |
| Ardelyx, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$114
How this compares
$5,085 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 241 | $317,120 |
| OzempicSemaglutide | 138 | $189,940 |
| LinzessLinaclotide | 95 | $102,375 |
| EliquisApixaban | 58 | $75,811 |
| JanuviaSitagliptin Phosphate | 81 | $75,038 |
| JardianceEmpagliflozin | 59 | $66,595 |
| FarxigaDapagliflozin Propanediol | 51 | $52,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $43,845 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $33,079 |
| TrulicityDulaglutide | 30 | $30,875 |
| LivaloPitavastatin Calcium | 56 | $30,419 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,044 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $18,583 |
| XareltoRivaroxaban | 19 | $16,650 |
| TradjentaLinagliptin | 18 | $16,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $417 | $347,995271 claims |
| Novo NordiskOzempic | $853 | $189,940138 claims |
| AbbVieLinzess, Synthroid | $293 | $105,167133 claims |
| Boehringer IngelheimJardiance, Tradjenta | $180 | $83,22777 claims |
| PfizerEliquis | $97 | $75,81158 claims |
| MerckJanuvia | $84 | $75,03881 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $289 | $71,10268 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $475 | $50,44046 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $282 | $30,41956 claims |
| Johnson & JohnsonXarelto, Invokana | $21 | $24,00131 claims |
| NovartisTekturna | $142 | $4,19811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Ashburn
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.